Cargando…

The role of health technology assessment bodies in shaping drug development

The use of health technology assessment (HTA) to inform policy-making is established in most developed countries. Compared to licensing agencies, HTA agencies have different interests and, therefore, different evidence requirements. Criteria for coverage or reimbursement decisions on pharmaceutical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciani, Oriana, Jommi, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234281/ https://www.ncbi.nlm.nih.gov/pubmed/25419117 http://dx.doi.org/10.2147/DDDT.S49935

Ejemplares similares

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
por: Drummond, Michael, et al.
Publicado: (2023)

EQ-5D-5L Population Norms for Italy
por: Meregaglia, Michela, et al.
Publicado: (2022)

Editorial: Near-infrared fluorescence guided surgery: State of the evidence from a health technology assessment perspective
por: Bertolaccini, Luca, et al.
Publicado: (2023)

Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence
por: Ciani, Oriana, et al.
Publicado: (2022)

Harnessing Digital Health Technologies During and After the COVID-19 Pandemic: Context Matters
por: Petracca, Francesco, et al.
Publicado: (2020)

Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials
por: Cucciniello, Maria, et al.
Publicado: (2021)

HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES
por: Ciani, Oriana, et al.
Publicado: (2015)

Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps
por: Tarricone, Rosanna, et al.
Publicado: (2022)

The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians
por: Sommariva, Silvia, et al.
Publicado: (2016)

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
por: Rognoni, Carla, et al.
Publicado: (2021)

The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency
por: Jommi, Claudio, et al.
Publicado: (2023)

Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
por: Ciani, Oriana, et al.
Publicado: (2021)

Health technology assessment of non-invasive interventions for weight loss and body shape in Iran
por: Nojomi, Marzieh, et al.
Publicado: (2016)

Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review
por: Ardito, Vittoria, et al.
Publicado: (2023)

Role of the Health Technology Assessment in Revising Health Insurance Benefits Package: Guiding or Shaping?
por: NOUHI, Mojtaba, et al.
Publicado: (2020)

Development and validation of the body shape scale (BOSHAS) for assessing body shape perception in African populations
por: Cohen, Emmanuel, et al.
Publicado: (2020)

The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022
por: Meregaglia, Michela, et al.
Publicado: (2023)

Shaping and Focusing Magnetic Field in the Human Body: State-of-the Art and Promising Technologies
por: Rotundo, Sabrina, et al.
Publicado: (2022)

The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study
por: Kållberg, Cecilia, et al.
Publicado: (2023)

The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy
por: Otto, Monica Hildegard, et al.
Publicado: (2018)

Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy
por: Otto, Monica Hildegard, et al.
Publicado: (2019)

Body Shaping and Volume Restoration: The Role of Hyaluronic Acid
por: Hedén, Per, et al.
Publicado: (2009)

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022
por: Ciani, Oriana, et al.
Publicado: (2023)

Generic Preference-based Measures for Low Back Pain: Which of Them Should Be Used?
por: Finch, Aureliano Paolo, et al.
Publicado: (2016)

Treatment effect bias in randomised controlled trials using surrogate outcomes: a preliminary cohort study analysis
por: Ciani, Oriana, et al.
Publicado: (2011)

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies
por: Izmailova, Elena S., et al.
Publicado: (2022)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy
por: Marras, Carlo Efisio, et al.
Publicado: (2020)

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review
por: Balijepalli, Chakrapani, et al.
Publicado: (2020)

Health care costs of influenza-related episodes in high income countries: A systematic review
por: Federici, Carlo, et al.
Publicado: (2018)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

The role of Iran's context for the development of health technology assessment: challenges and solutions
por: Behzadifar, Meysam, et al.
Publicado: (2023)

Combination of drugs and carriers in drug delivery technology and its development
por: Du, Ying, et al.
Publicado: (2019)

Variables affecting pricing of orphan drugs: the Italian case
por: Jommi, Claudio, et al.
Publicado: (2021)

PET technology for drug development in psychiatry
por: Arakawa, Ryosuke, et al.
Publicado: (2020)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review
por: Oprea, Natalia, et al.
Publicado: (2023)

Comment on The Unbearable Lightness of Difference Between Statistical and Clinical Significance
por: Bertolaccini, Luca, et al.
Publicado: (2022)

PNS78 Impact of COVID on Health Technology Assessment bodies
por: Macaulay, R.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8b4fv8ip4v21j5mb8cf5i4gqm0